Explore the vast range of titles available.

Omalizumab, a humanized anti-IgE monoclonal antibody, is commonly employed in the treatment of antihistamine-refractory chronic spontaneous urticaria (CSU), where it significantly reduces free IgE levels, minimizing histamine release from basophils and mast cells. Despite its efficacy, there are concerns regarding its effect on parasitic defense due to IgE's role in combating parasitic infestations. We present a case of a 28-year-old female agriculturist with a six-month history of CSU who experienced a paradoxical exacerbation of her symptoms following an increase in the omalizumab treatment dose. This deterioration coincided with a serologically confirmed parasitic infection with and . Despite normal eosinophil counts and IgE levels, which are typically used to identify parasitic infections, the patient's clinical worsening prompted further investigation that led to the identification of the parasitic infection. Treatment with albendazole and omalizumab discontinuation led to the resolution of her CSU, suggesting that the parasitic infection was contributing to the symptom exacerbation. This case highlights the need for careful screening for parasitic infections before initiating omalizumab in antihistamine-refractory CSU patients from endemic regions, or patients who deteriorate clinically on omalizumab, especially when other indicators such as eosinophil count and IgE levels might not suggest infection. It also underscores the importance of considering a tailored approach to managing CSU that balances effective treatment with the potential for adverse effects related to immunomodulation.

Chronic spontaneous urticaria (CSU) is a complex inflammatory skin condition that severely impacts patients' quality of life. For some patients, conventional treatments, including second-generation antihistamines, omalizumab, and cyclosporine A, fail to achieve sustained control. Emerging evidence suggests that psychiatric comorbidities, such as generalized anxiety disorder (GAD), exacerbate CSU through neuro-immuno-cutaneous (the interaction between the nervous system, immune system, and skin) mechanisms. We present the case of a 35-year-old female with refractory CSU and GAD. Despite escalating doses of omalizumab and the addition of cyclosporine A, disease control remained unstable. The introduction of cognitive behavioral therapy (CBT) and escitalopram resulted in significant improvement, achieving complete resolution of symptoms within eight weeks. Following discontinuation of both escitalopram and omalizumab, urticaria relapsed after a stressful event and during pregnancy. The reintroduction of escitalopram and CBT reestablished full control of urticaria. The patient continues on escitalopram and CBT without needing additional pharmacological intervention for CSU. This case underscores the importance of incorporating mental health interventions in managing refractory CSU, as psychiatric comorbidities may exacerbate CSU by intensifying neuro-immune interactions, particularly during stressful periods. Integrating mental health care into treatment guidelines can offer significant benefits, improving symptom control, reducing the need for aggressive pharmacotherapy, and enhancing patients' quality of life.

Background Chronic urticaria (CU) is a heterogeneous skin disorder whose genetic drivers are incompletely defined. Objective To systematically review and meta‐analyse genetic and epigenetic factors that influence susceptibility and treatment response in acute and CU. Methods Following Preferred Reporting Items for Systematic Reviews and Meta‐Analyses guidelines, PubMed, Scopus and Web of Science were searched from inception to 31 July 2024. Original human studies reporting genetic or epigenetic associations with any urticaria subtype were eligible. Random‐effects meta‐analyses were undertaken when at least three comparable datasets were available. Results Sixty‐one studies met the inclusion criteria. Associations were confirmed for HLA‐B44 (pooled Odds Ratio 8.15, 95% Confidence Interval 1.61–41.29; I2 = 86%) and vitamin‐D‐receptor polymorphisms FokI, TaqI and BsmI, each conferring a 1.5‐ to 2.1‐fold increased risk. Variants in CRTH2, FcεR1α and C‐reactive protein predicted antihistamine response, while FCER1G, IL‐6, prostaglandin‐endoperoxide synthase 2, CCL2 and TNF‐pathway genes were over‐expressed in lesional tissue, supporting an immune‐mediated pathogenesis. Evidence for non‐CSU subtypes, acute urticaria, epigenetic modifications and gene–environment interactions was limited. Conclusions CU displays an autoimmune‐like genetic signature. HLA‐B44 and vitamin D receptor variants are susceptibility markers, and pharmacogenetic signals enable personalised therapy. Longitudinal studies integrating environmental exposures and functional genomics are needed to translate these insights into precision care.

Background: Primary scarring alopecias (PSAs) are a rare group of dermatological disorders with overlapping clinical features. They result in permanent hair loss and significant psychological morbidity. Aims: To analyze the clinico-epidemiology of PSAs of the scalp, along with clinico-pathological correlation. Methods: We conducted a cross sectional, observational study including 53 histopathologically confirmed cases of PSA. Clinico-demographic parameters, hair care practices, and histologic characteristics were noted and statistically analyzed. Results: Among 53 patients (mean age 30.9 ± 8.1 years, M: F 1:1.2, median duration 4 years) with PSA, lichen planopilaris (LPP) was most common (39.6%, 21/53), followed by pseudopelade of Brocq [30.2%, 16/53], discoid lupus erythematosus (DLE) [16.9%, 9/53], and non-specific scarring alopecia (SA) (7.5%, 4/53), while central centrifugal cicatricial alopecia (CCCA), folliculitis decalvans, and acne keloidalis nuchae (AKN) accounted for 1 case each. Forty-seven patients (88.7%) demonstrated predominant lymphocytic inflammatory infiltrate, while basal cell degeneration and follicular plugging were the commonest histological changes. Perifollicular erythema and dermal mucin deposition were noted in all patients with DLE (both P < 0.05). Nail involvement (P = 0.004) and mucosal involvement (P = 0.8) were more common in LPP. Single alopecic patches were characteristic of DLE and CCCA. Hair care practices (non-medicated shampoo > oil) had no significant association with the subtype of PSA. (P = 0.4) Conclusion: PSAs are a diagnostic challenge for dermatologists. Thus, histology and clinico-pathological correlation should be performed in all cases for proper diagnosis and treatment.

Background: Acne vulgaris is a chronic inflammatory disease primarily affecting the adolescents, with a profound impact on their quality of life. There is conflicting data regarding its association with metabolic syndrome. Objective: To assess the prevalence of metabolic syndrome (MetS) and obesity in patients with acne vulgaris, and determine its impact on the patient's quality of life. Methods: We conducted a cross-sectional, case-control study involving 50 patients with acne vulgaris (cases) and 50 age and sex-matched controls without acne. Acne vulgaris was graded according to clinical severity using the GAGS scale. NCEP-ATP III criteria and modified classification of body mass index (BMI) for Asian Indians were used to diagnose MetS and obesity, respectively, in both cases and controls. We used the DLQI questionnaire to evaluate its impact on the quality of life. Results: Cases and controls were comparable with respect to parameters like age, BMI, systolic blood pressure (SBP), diastolic blood pressure (DSBP), and serum triglyceride while fasting blood sugar (FBS, case > control) and serum high-density lipoprotein (HDL, control > case) were significantly different (P < 0.05, independent t-test). Prevalence of MetS was higher in cases (32%) than controls (14%), though comparable (P = 0.06, Chi-square). Only SBP, FBS, and serum HDL showed a significant correlation with the severity of acne. Obesity was comparable between cases (18%) and controls (10%), without any relation to acne severity. Acne exerted a moderate impact on the quality of life (mean DLQI 9.3). Severe acne showed higher DLQI, although their correlation was not statistically significant (P = 0.8, ANOVA). Conclusion: Although acne patients may develop MetS and obesity, there is a lack of significant association. Thus, we should examine all obese patients, irrespective of dermatological disorder, to rule out metabolic syndrome. Acne also affects the patient's quality of life, thus emphasizing the need for additional psychosocial counselling.

Psoriatic arthritis (PsA), an inflammatory seronegative spondyloarthropathy is the most common co-morbidity of psoriasis (PsO), in almost 30% of cases. Delayed diagnosis and treatment of PsA may result in irreversible joint damage, significant morbidity, impaired quality of life, and several cardiometabolic and cerebrovascular co-morbidities. Dermatologists are uniquely privileged to be able to diagnose latent PsA at an early stage, as almost 80% of these patients present with pre-existing cutaneous PsO. This review provides a detailed overview of PsA along with its salient clinical features, classification criteria, screening tools, simple physical examination maneuvers, imaging findings, and therapeutic options to acquaint dermatologists and other clinicians with this morbid musculoskeletal disorder. We hope to generate awareness about this condition among dermatologists to enable proactive screening of all PsO patients for early diagnosis, initiation of appropriate treatment, and prompt referral to a rheumatologist; thus, helping to arrest PsA disease progression, irreversible joint damage, and subsequent permanent disability.

Background: Frontline doctors engaged in COVID-19 duties have to adopt enhanced protective measures to minimize their risk of exposure. However, these measures may lead to several skin problems, thereby affecting their performance. Objectives: To analyze skin changes induced by enhanced protective measures and explore possible risk factors. Materials and Methods: A web-based descriptive study was conducted among 212 frontline COVID-19 doctors. Data were collected regarding their demography, duty, use of enhanced protective measures including prophylactic hydroxychloroquine, recent skin changes with affected sites, and possible risk factors. Results: Skin changes were reported by 41.5% of respondents (mean age 34.8 ± 5.6 years) across 210 sites. Hands were involved most commonly in 77.3% of doctors, followed by nasal bridge, cheeks, and retroauricular area. Dryness (84.1%) and skin peeling (79.5%) were the commonest clinical features. Regression model showed prolonged PPE wear (>6 h) adjusted odd's ratio (AOR) 2.9, P = 0.005], heavy sweating [AOR 12.8, P = 0.001] and frequent hand hygiene (>10 times/day) [AOR 3.1, P = 0.0006] to be significant risk factors. Hydroxychloroquine prophylaxis was deemed safe as treatment-emergent adverse events were uncommon (17.4%). Conclusion: Frontline doctors have an increased risk of developing skin damage due to enhanced protective measures. Appropriate steps should be taken to address the risk factors and minimize skin damage. Persistent cases mandate dermatology referral for optimum management.

Background Omalizumab is the recommended treatment for antihistamine‐refractory chronic spontaneous urticaria (CSU) and severe allergic asthma. In addition, it has been shown to reduce the frequency of viral respiratory infections in allergic asthma. Respiratory illness is a known trigger for asthma and CSU. Objectives To explore whether the antiviral effect of omalizumab may be extended to CSU patients independent of their atopic status. Methods We conducted a prospective parallel‐group pilot pragmatic trial including 30 non‐allergic and non‐atopic CSU patients (cases) under omalizumab 300 mg Q4‐weeks (due to refractory to H1‐antihistamines) and 30 age‐matched healthy controls. All CSU patients had to have a weekly urticaria activity score UAS7 <15 at least 4 weeks before recruitment. Using the self‐filled validated Jackson scale, we evaluated all study participants for common cold symptoms. All cases and controls rated weekly their respiratory symptoms. An increase in the symptom score of at least 4 points compared to baseline (defined as the minimum weekly report of symptoms) was considered an episode suggestive of a viral infection of the upper respiratory tract (URT). The patients were follow‐up every 4 weeks throughout the study period (10 months). Results CSU patients under omalizumab reported fewer episodes suggestive of an URT viral infection than the healthy controls (median of reported episodes: 0 vs. 1, inter‐quartile range 0–1 vs. 1–1, min–max: 0–3 vs. 0–4, respectively; p = 0.0095). The duration of each episode was the same in both cases and controls. Conclusions Omalizumab can reduce the number of common cold episodes in CSU patients and consequently may minimize viral‐related CSU exacerbations. This beneficial effect is exerted independently of the atopic status, even in non‐asthmatic individuals or non‐allergic patients without any evidence of respiratory susceptibility. Further large‐scale studies are needed to validate the current findings and elucidate the underlying relevant pathophysiology.

Background: Chikungunya fever is a common viral illness in the tropical and subtropical areas. Various cutaneous manifestations can develop during the acute phase and post-febrile convalescent phase. Objective: To determine the frequency and types of cutaneous manifestations associated with chikungunya fever in acute and post-febrile phase. Methods: We conducted a prospective, observational study including 20 patients with laboratory-confirmed chikungunya fever. All the patients were followed up for 1 year to detect any cutaneous sequelae. Results: Pruritic maculopapular rash was the most common cutaneous manifestation during the acute febrile phase, noted in 60% of the patients. The rash usually appeared within 1-3 days of fever onset and spread in cephalo-caudal direction. Cutaneous hyperpigmentation was the most common dermatologic sequelae in the post-febrile period, occurring in 3 (15%) patients. In all patients, pigmentation appeared 3-4 weeks after resolution of fever, and started on the nose, gradually spreading to the forehead. The pigmentation improved significantly with topical hydroquinone after 4 weeks. Other additional manifestations of chikungunya fever included joint pain and joint swelling. None of our patients presented with mucosal or systemic involvement. Conclusion: Maculopapular skin rash was the most common manifestation during acute febrile phase of chikungunya fever, while cutaneous hyperpigmentation was the most common dermatologic sequelae after resolution of fever.